← Back to Search

Cannabinoid

Cannabigerol for Well-being

N/A

Waitlist Available

Led By Cory Rice, D.O.

Research Sponsored by Formula30A LLC

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 8 weeks

Awards & highlights

Study Summary

This trial studies the physical and mental effects of taking cannabigerol (CBG) over 12 weeks to see if it helps people feel better.

Who is the study for?

This trial is for healthy adults over 21 who aren't using marijuana or other cannabinoids, haven't started new meds recently, and don't have liver issues or a history of substance abuse. Those who could get pregnant must use effective contraception or abstain from sex.Check my eligibility

What is being tested?

The study tests the effects of daily oral consumption of 50mg full spectrum CBG on well-being and inflammation in adults. It involves initial health surveys, regular blood tests to check inflammation markers, taking CBG for 8 weeks followed by a washout period.See study design

What are the potential side effects?

Potential side effects are not specified but will be monitored through clinical visits and self-reported questionnaires focusing on any adverse reactions participants might experience during the trial.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 8 weeks

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~8 weeks

This trial's timeline: 3 weeks for screening, Varies for treatment, and 8 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Change from Baseline Erythrocyte Sedimentation Rate (ESR) at 8 weeks

Change from Baseline High-Sensitivity C-reactive Protein (hsCRP) at 8 weeks

Change from Baseline Medical Symptom Questionnaire (MSQ) Score at 8 weeks

+2 more

Trial Design

1Treatment groups

Experimental Treatment

Group I: 50mg CBG CapsuleExperimental Treatment1 Intervention

50mg cannabigerol (CBG) oil capsule taken daily for 8 weeks. Study surveys and bloodwork completed for 12 weeks total, including 8 weeks of CBG treatment and subsequent 4-week washout period

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Formula30A LLCLead Sponsor

1 Previous Clinical Trials

30 Total Patients Enrolled

Cory Rice, D.O.Principal InvestigatorModern Medicine

Media Library

Inflammation Research Study Groups: 50mg CBG Capsule

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there any Canadian locales in which this experiment is being conducted?

"6 clinical sites are running this investigation, and they span from Denton to Edinburg and Forney. To reduce the need for unnecessary travel, participants should select the nearest site when enrolling in this trial."

Answered by AI

Are any more participants sought for this clinical trial?

"As reported on clinicaltrials.gov, this study is not currently recruiting patients; with the trial having been posted on August 1st 2022 and last edited February 15th 2023. However, there are presently 50 alternative medical trials which are actively seeking candidates."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Efficacy and Safety of Hemp-derived, Full Spectrum Cannabigerol (CBG) in Adults

2022. "Efficacy and Safety of Hemp-derived, Full Spectrum Cannabigerol (CBG) in Adults". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05743985.